

Release of Shares from Voluntary Escrow

Medibio Limited (**MEB** or the **Company**) announces that restricted securities as outlined in Table 1 below are due for release from escrow on 7 April 2016.

The shares are held by the founders of Medibio's CHR technology for the diagnosis of depression, chronic stress, and other mental health disorders. Each of the founders is actively involved in assisting Medibio to advance the company's depression diagnostic towards FDA submission and Corporate Stress product towards significant generation.

In addition to the securities which are coming out of escrow each of the founders has had free trading Medibio shares since April 2015 none of which have been sold.

Table 1 – Restricted Securities Due for Release April 7 2015

| Security description | Release Date | Number |
|--------------------------------|--------------|------------|
| Ordinary fully paid restricted | 7 April 2016 | 23,929,979 |

About Medibio Limited

Medibio (ASX: MEB), is a medical technology company that has developed an objective test to assist in the diagnosis of depression, chronic stress, and other mental health disorders. Based on research conducted over 15 years at the University of Western Australia, this test utilizes patented (pending) circadian heart rate variability and cloud based proprietary algorithms to deliver a quantifiable measure to assist in a clinical diagnosis. Studies are currently being undertaken by Johns Hopkins University School of Medicine and Ottawa University, among others, to validate the clinical utility of the test. This will potentially enable Medibio's technology to be the first FDA approved, objective, evidence based approach to the diagnosis of mental health disorders for the medical industry. The technology also provides an objective method for the assessment of stress and mental wellbeing which can be translated to the workplace stress/wellbeing market, wearable technology, and App market. Located in Sydney, NSW, Medibio is listed on the Australian Stock Exchange.

| Further Information: | | Website: www.medibio.com.au | |
|--|--|---|--|
| Medibio Shareholder Enquiries to: Kris Knauer CEO and Director Medibio Limited kris.knauer@medibio.com.au T: +61 (0)411 885 979 | | Medibio Media Enquiries to: Peter Taylor NWR Communications peter@nwrcommunications.com.au T: +61 (0)412 036 231 | |